Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis

被引:9
|
作者
Tan, Chongqing [1 ]
Luo, Xia [1 ]
Zhou, Zhen [2 ]
Zeng, Xiaohui [3 ]
Wan, Xiaomin [1 ]
Yi, Lidan [1 ]
Liu, Qiao [1 ,4 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Peoples R China
[2] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[3] Cent South Univ, Xiangya Hosp 2, PET CT Ctr, Changsha, Peoples R China
[4] Ctr South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Hunan, Peoples R China
关键词
Omicron; Dynamic zero-COVID strategy; Shanghai; China; Cost-effectiveness; DISEASE; BURDEN; WAVE;
D O I
10.1016/j.jiph.2023.04.005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The sustainability and generalizability of China's dynamic zero-COVID strategy on eliminating SARS-CoV-2 transmission has casted doubt globally, mainly because it has exacted high social and economic cost. This study aimed to estimate the disease burden during the first wave of Omicron in China and compared the cost-effectiveness of implementing a Real-world strategy (adjusted dynamic zero-COVID strategy) with two simulated strategies (routine and stricter dynamic zero-COVID strategy) to inform appropriate strategies for COVID-19 pandemic control. Methods: A dynamic state-transition simulation model was developed to compare the health and cost outcomes between different dynamic zero-COVID strategies. Omicron-related healthcare costs were estimated from the societal perspective. Epidemiological parameter values were derived from data of realworld or generated by model calibration; costs and effectiveness parameter values were informed either by local data or published literature. The primary outcomes were total social cost, disability adjusted life-years (DALYs) and net monetary benefit (NMB). Deterministic sensitivity analyses (DSA) and scenario analyses were performed to assess the model robustness. Results: The first wave of Omicron in Shanghai resulted in 47,646 DALYs lost and 415 billion RMB losses. At a willingness-to-pay threshold of 173,630 RMB (the GDP per capita of Shanghai in 2021) per DALY saved, the Real-world strategy was considered as the most cost-effective strategy due to its highest NMB (-407 billion). Results from DSA confirmed the robustness of our findings. Conclusion: Our finding supported the Real-world strategy taken by the Shanghai Municipal Government between March 1 and May 21, 2022 to control the first wave of Omicron outbreak. Moreover, our results indicated that whether the Stricter dynamic zero-COVID strategy is worth implementing at the beginning of the COVID-19 outbreak mainly depended on the infection rate of COVID-19 among primary contacts. Our analysis provides important evidence to inform policy makers to make appropriate decisions regarding COVID-19 pandemic management. (c) 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:893 / 900
页数:8
相关论文
共 50 条
  • [31] Was China's zero-COVID policy the right choice? The multiple factor analysis of variables that affected the course of COVID-19 pandemic in China
    Sobczak, Marharyta
    Pawliczak, Rafal
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [32] Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
    Orangi, Stacey
    Ojal, John
    Brand, Samuel P. C.
    Orlendo, Cameline
    Kairu, Angela
    Aziza, Rabia
    Ogero, Morris
    Agweyu, Ambrose
    Warimwe, George M.
    Uyoga, Sophie
    Otieno, Edward
    Ochola-Oyier, Lynette, I
    Agoti, Charles N.
    Kasera, Kadondi
    Amoth, Patrick
    Mwangangi, Mercy
    Aman, Rashid
    Ng'ang'a, Wangari
    Adetifa, Ifedayo M. O.
    Scott, J. Anthony G.
    Bejon, Philip
    Keeling, Matt J.
    Flasche, Stefan
    Nokes, D. James
    Barasa, Edwine
    BMJ GLOBAL HEALTH, 2022, 7 (08):
  • [33] Cost-effectiveness and Accuracy Analysis of Different Screening Strategies for COVID-19
    Cheng, Chih-Chien
    Liu, Chia-Chen
    Liu, Hao-Yu
    Chou, Yi-Chang
    Yen, Yung-Feng
    Chiu, Yi-Chun
    Fann, Li-Yun
    Chou, Chuan-Yi
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2024,
  • [34] Cost-effectiveness analysis of COVID-19 tests in the unified health system
    Vinicius Queiroz Miranda Cedro
    Stéfany de Lima Gomes
    Ana Clara Correa Duarte Simões
    Tatiana do Valle Lovato Sverzut
    Keila Cristina Xavier Bertti
    Marcelo Tadeu Tristão
    Yuri Wanderley Cavalcanti
    João Victor Frazão Câmara
    Antonio Carlos Pereira
    Cost Effectiveness and Resource Allocation, 21
  • [35] Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients
    Chow, Ronald
    Simone, Charles B., II
    Prsic, Elizabeth Horn
    Shin, Hyun Joon
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (07) : 2285 - 2290
  • [36] The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context
    Kristian Debrabant
    Lone Grønbæk
    Christian Kronborg
    Clinical Drug Investigation, 2021, 41 : 975 - 988
  • [37] The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context
    Debrabant, Kristian
    Gronbaek, Lone
    Kronborg, Christian
    CLINICAL DRUG INVESTIGATION, 2021, 41 (11) : 975 - 988
  • [38] THE COST-EFFECTIVENESS OF COVID-19 LOCKDOWNS IN THE UNITED STATES
    Becker, R.
    VALUE IN HEALTH, 2020, 23 : S566 - S566
  • [39] The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
    Whittington, Melanie D.
    Pearson, Steven D.
    Rind, David M.
    Campbell, Jonathan D.
    VALUE IN HEALTH, 2022, 25 (05) : 744 - 750
  • [40] Cost-effectiveness of COVID-19 vaccination: A systematic review
    Fu, Yaqun
    Zhao, Jingyu
    Han, Peien
    Zhang, Jiawei
    Wang, Quan
    Wang, Qingbo
    Wei, Xia
    Yang, Li
    Ren, Tao
    Zhan, Siyan
    Li, Liming
    JOURNAL OF EVIDENCE BASED MEDICINE, 2023, 16 (02) : 152 - 165